Novel approaches for the rapid development of rationally designed arbovirus vaccines.

Autor:	van Bree JWM; Laboratory of Virology, Wageningen University & Research, Wageningen, the Netherlands., Visser I; Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands., Duyvestyn JM; Department of Medical Microbiology, Leiden University Medical Centre, Leiden, the Netherlands., Aguilar-Bretones M; Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands., Marshall EM; Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands., van Hemert MJ; Department of Medical Microbiology, Leiden University Medical Centre, Leiden, the Netherlands., Pijlman GP; Laboratory of Virology, Wageningen University & Research, Wageningen, the Netherlands., van Nierop GP; Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands., Kikkert M; Department of Medical Microbiology, Leiden University Medical Centre, Leiden, the Netherlands., Rockx BHG; Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands., Miesen P; Department of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, P.O. Box 9101, 6500, HB, Nijmegen, the Netherlands., Fros JJ; Laboratory of Virology, Wageningen University & Research, Wageningen, the Netherlands.
Jazyk:	angličtina
Zdroj:	One health (Amsterdam, Netherlands) [One Health] 2023 May 13; Vol. 16, pp. 100565. Date of Electronic Publication: 2023 May 13 (Print Publication: 2023).
DOI:	10.1016/j.onehlt.2023.100565
Abstrakt:	Vector-borne diseases, including those transmitted by mosquitoes, account for more than 17% of infectious diseases worldwide. This number is expected to rise with an increased spread of vector mosquitoes and viruses due to climate change and man-made alterations to ecosystems. Among the most common, medically relevant mosquito-borne infections are those caused by arthropod-borne viruses (arboviruses), especially members of the genera Flavivirus and Alphavirus . Arbovirus infections can cause severe disease in humans, livestock and wildlife. Severe consequences from infections include congenital malformations as well as arthritogenic, haemorrhagic or neuroinvasive disease. Inactivated or live-attenuated vaccines (LAVs) are available for a small number of arboviruses; however there are no licensed vaccines for the majority of these infections. Here we discuss recent developments in pan-arbovirus LAV approaches, from site-directed attenuation strategies targeting conserved determinants of virulence to universal strategies that utilize genome-wide re-coding of viral genomes. In addition to these approaches, we discuss novel strategies targeting mosquito saliva proteins that play an important role in virus transmission and pathogenesis in vertebrate hosts. For rapid pre-clinical evaluations of novel arbovirus vaccine candidates, representative in vitro and in vivo experimental systems are required to assess the desired specific immune responses. Here we discuss promising models to study attenuation of neuroinvasion, neurovirulence and virus transmission, as well as antibody induction and potential for cross-reactivity. Investigating broadly applicable vaccination strategies to target the direct interface of the vertebrate host, the mosquito vector and the viral pathogen is a prime example of a One Health strategy to tackle human and animal diseases. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2023 The Authors. Published by Elsevier B.V.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu